Covid-19 vaccine maker BioNTech is looking to build malaria and tuberculosis vaccine production sites in Rwanda and Senegal, narrowing its search for African locations.
The future malaria and tuberculosis vaccines would be based on the so-called messenger RNA (mRNA) technology, also used in its Covid-19 shot, the German drug maker said. BioNTech did not say when production was likely to start. In July it said it would seek to develop a malaria vaccine, eyeing production in Africa, as it seeks to build on its success with its partner, Pfizer, in Covid shots...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.